11-17-04   *IFW*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
	)
Li-Huei Tsai, Ming-Sum Lee, and Jonathan Cruz	) Examiner:
	)
	)
Serial No.: 10/625,986	) Art Unit: 1614
	)
Filed: July 24, 2003	)
	)
Title: COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS	)))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

In regard to the above identified application, we are transmitting herewith the attached:

1.   Supplemental Information Disclosure Statement (2 pages),
2.   PTO Form-1449 (1 page),
3.   Copies of three (3) references, and
4.   Return postcard.

With respect to additional fees, no fees are due. The Commissioner is nonetheless authorized to charge any additional fees or credit overpayment to Deposit Account No. 19-0733.

Respectfully submitted,

Dated: _November 16, 2004_   By _____
                                      John P. Iwanicki, Reg. No. 34,628
                                      BANNER & WITCOFF, LTD.
                                      28 State Street, 28th Floor
                                      Boston, MA 02109
                                      (617) 720-9600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
   Li-Huei Tsai, Ming-Sum Lee, and   ) Examiner:
   Jonathan Cruz   )
)
Serial No.:   10/625,986   ) Art Unit: 1614
)
Filed: July 24, 2003   )
)
Title: COMPOUNDS AND METHODS FOR TREATING)
     NEURODEGENERATIVE DISORDERS   )

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.97-1.99, Applicants hereby submit the enclosed PTO Form 1449. Copies of the references are enclosed.

This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56 and is being submitted before the mailing date of a first Office Action on the merits.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This

USSN 10/625,986
Express Mail receipt no. EV 396914941 US

statement is not a representation that the listed references have effective dates early enough to be

"prior art" within the meaning of 35 U.S.C. § 102 or § 103.

Please apply any charges or credits to Deposit Account No. 19-0733.

Respectfully submitted,

Dated: ___November 16, 2004___   By ___[signature]___
John P. Iwanicki, Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
(617) 720-9600

USPTO Form 1449		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 10498-00054		Serial No. 10/625,986	
			Applicants: **Li-Huei Tsai et al.**			
INFORMATION DISCLOSURE CITATION Sheet 1 of 1			Filing Date: **July 24, 2003**			Group: **1614**

U.S. PATENT DOCUMENTS

Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
	AH							
	AI							
	AJ							
	AK							
	AL							
	AM							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	AN	Cruz et al., "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles," *Neuron.*, 40(3):471-483 (2003)
	AO	Wang et al., "Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors," *Nat. Neurosci.*, 6(10):1039-1047 (2003)
	AP	Zhang et al., "Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice," *Am J Pathol.*, 165(3):843-853 (2004)
	AQ	
	AR	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.**Copies of references not provided at the time of this submission.